ERBB2 and breast cancer: Following the same line, MONARCH-3 was a phase III, randomised (2:1), double-blind clinical trial which included 493 patients with breast cancer, positive hormone receptors, and HER-2 negative who presented with locoregional recurrence or distant metastasis.